Vijoice®(alpelisib) – New orphan drug approval
April 6, 2022 - Novartis announced the FDA approval of Vijoice (alpelisib), for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
Download PDF
